0 Produkte - CHF 0.00
  Zum Warenkorb

L. reuteri 5289 & 17938*

Die Mundmikrobiota ist nach der Darmflora die zweitgrösste mikrobielle Gemeinschaft im menschlichen Körper. Sie besteht hauptsächlich aus Bakterien, die im oralen Biofilm leben und gedeihen.

Die Mehrheit dieser Bakterien sind Kommensalen, die auf unser Immunsystem wirken können, um schützende Reaktionen auszulösen, die eine Besiedlung und Invasion durch Pathogene verhindern. Ein kleiner Teil sind jedoch Pathogene, die mit Parodontalerkrankungen in Verbindung gebracht werden, wie Aggregatibacter actinomycetemcomitans (A. actinomycetemcomitans) und Porphyromonas gingivalis (P. gingivalis).

In einem gesunden Mund können die guten Bakterien die Pathogene in Schach halten.

Klinische Studien

weiterlesen...

Die Kombination von L. reuteri 5289 & 17938 konnte klinisch nachweisen, dass sie das Gleichgewicht der Mundmikrobiota fördert und somit einen natürlichen Schutz bei Problemen im Mund bietet.

L. reuteri 5289 & 17938 ist klinisch nachgewiesen, um:

  • Streptococcus mutans bei Kindern und Erwachsenen zu reduzieren
  • Gingivitis zu reduzieren
  • die Ergebnisse der professionellen Reinigung bei Patienten mit Parodontitis zu verbessern
  • klinische Parameter bei Patienten mit Zahnimplantaten zu verbessern

Anwendungsbereich
für L. reuteri 5289 & 17938

Anwendungsbereich für L. reuteri Prodentis

Wirkungsweise L. reuteri 5289 & 17938

Klinische Studien / Artikel

55 klinische Studien mit L. reuteri 5289 & 17938 bei 2'917 Studienteilnehmer!

Gingivitis & Schwangerschafts-gingivitis

weiterlesen...

Parodontitis

weiterlesen...

Periimplantäre Mukositis & Periimplantitis

weiterlesen...

Andere Studien zur Mundgesundheit

weiterlesen...

Karies

16 klinische Studien. 4 davon bei Kindern und 12 bei Erwachsenen. Es folgen einige Artikel.

  • Effect of drops containing Lactobacillus reuteri (DSM 17938 and ATCC PTA 5289) on plaque acidogenicity and other caries-related variables in orthodontic patients

    Alforaidi S. et al., BMC Microbiol. 2021 Oct 6;21(1):271. doi: 10.1186/s12866-021-02310-2.

    Study Objectives: Evaluate the effect of drops containing L. reuteri Prodentis on plaque pH and the number of S. mutans and lactobacilli in orthodontic patients.

    Study Design: R, DB, PC, 3 weeks

    Subjects and daily dose: 13 patients L. reuteri, 14 patients Placebo

    Results: Significant increase in plaque pH at three weeks in the probiotic group (p<0.05), while insignificant changes in the pH value were found for the placebo group in comparison to baseline (p > 0.05). No difference in the number of S. mutans and lactobacilli between the groups.

  • Salivary mutans streptococci and lactobacilli levels after ingestion of the probiotic bacterium Lactobacillus reuteri ATCC 55730 by straws or tablets

    Caglar E. et al., Acta Odontol Scand. 2006 Oct;64(5):314-8. doi: 10.1080/00016350600801709.

    Study Objectives: To study the effect of L. reuteri ATCC 55730 in two non-dairy delivery systems, on mutans streptococci and lactobacilli in adults.

    Study Design: R, DB, PC, 3 weeks

    Subjects and daily dose: 30 patients L. reuteri drinking straw (1x108 CFU), 30 patients L. reuteri chewable tablet (1x108 CFU), 30 patients Placebo chewable tablet

    Results: L. reuteri delivered in a drinking straw or as a chewable tablet significantly reduced the counts of mutans streptococci compared to placebo.

  • Effect of Probiotic Lactobacillus reuteri on Salivary Cariogenic Bacterial Counts among Groups of Preschool Children in Jeddah, Saudi Arabia: A Randomized Clinical Trial

    Alamoudi N. M. et al., J Clin Pediatr Dent. 2018;42(5):331-338. doi: 10.17796/1053-4625-42.5.2.

    Study Objectives: To evaluate the effect of L. reuteri Prodentis lozenges on caries-associated salivary bacterial counts (mutans streptococci and lactobacilli), dental plaque accumulation, and salivary buffer capacity in preschool children (3-6y).

    Study Design: R, DB, PC, 28 days

    Subjects and daily dose: 90 patients L. reuteri (4x108 CFU), 88 patients Placebo

    Results: L. reuteri significantly reduced mutans streptococci and lactobacilli, compared to placebo. However, there was no difference in plaque accumulation or buffer capacity between the groups.

  • Effectiveness of CRT at measuring the salivary level of bacteria in caries prone children with probiotic therapy

    Cannon M. et al., J Clin Pediatr Dent. 2013 Fall;38(1):55-60. doi: 10.17796/jcpd.38.1.b481624264142082.

    Study Objectives: To evaluate and compare microbiological anti-caries effects of two probiotics: PerioBalance (=L. reuteri Prodentis) lozenges (Lr) and EvoraKids chewable tablets (EvK, blend of three streptococci strains), in children aged 6-12y and with moderate to high risk of caries. Both healthy and medically compromised children were included.

    Study Design: R, open, 28 days with Lr, 30 days with EvK, Evaluation 8 weeks after start of intervention

    Subjects and daily dose: 30 patients L. reuteri (2x108 CFU), 30 patients probiotic mix

    Results: Both probiotics suppressed the level of mutans streptococci and lactobacilli, compared to baseline. The difference between the two probiotics was non-significant. (The CRT (Caries Risk Test) Bacteria Kit was applied for microbiological evaluations. It allows simultaneous determination of mutans streptococci and lactobacilli counts in saliva by means of selective agars.

  • A novel delivery system of probiotic drop and its effect on dental caries risk factors in cleft lip/palate children

    Kavaloglu Cildir S. et al., Cleft Palate Craniofac J. 2012 May;49(3):369-72. doi: 10.1597/10-035.

    Study Objectives: To study effects on salivary mutans streptococci and lactobacilli in 4-12y old children with cleft lip/palate by use of L. reuteri Prodentis drops.

    Study Design: R, DB, PC, crossover 25 days per product

    Subjects and daily dose: 19 patients L. reuteri (2x108 CFU), 19 patients Placebo

    Results: L. reuteri Prodentis drops did not reduce the salivary counts of mutans streptococci or total lactobacilli.

  • Effect of tablets containing probiotic bacteria (Lactobacillus reuteri) on early caries lesions in adolescents: a pilot study

    Keller M. K. et al., Benef Microbes. 2014 Dec;5(4):403-7. doi: 10.3920/BM2013.0089.

    Study Objectives: To investigate the effect of L. reuteri Prodentis on early caries lesions in adolescents, aged 12-17 years, as measured by quantitative lightinduced fluorescence.

    Study Design: R, DB, PC, 12 weeks

    Subjects and daily dose: 19 patients L. reuteri (4x108 CFU), 17 patients Placebo

    Results: There were no statistically significant differences in fluorescence values and lesion area between the groups, neither at baseline, nor at the follow-up. Compared to baseline, there was a significant decrease in fluorescence at 12 weeks in the test group but not in the placebo group.

Gingivitis & Schwangerschaftsgingivitis

10 klinische Studien. Es folgen einige Artikel.

  • Consumption of Lactobacillus reuteri-containing lozenges improves periodontal health in navy sailors at sea: A randomized controlled trial

    Schlagenhauf U. et al., J Periodontol. 2020 Oct;91(10):1328-1338. doi: 10.1002/JPER.19-0393.

    Study Objectives: Investigate the effect of L. reuteri Prodentis on gingival inflammation in healthy adults.

    Study Design: R, DB, PC

    Subjects and daily dose: 36 patients L. reuteri (4x108 CFU), 36 patients Placebo

    Results: Compared to placebo, L. reuteri significantly improved bleeding of probing (primary outcome), as well as gingival index, plaque control record, probing pocket depth and probing attachment level (secondary outcomes).

  • Regular consumption of Lactobacillus reuteri-containing lozenges reduces pregnancy gingivitis: an RCT

    Schlagenhauf U. et al., J Clin Periodontol. 2016 Nov;43(11):948-954. doi: 10.1111/jcpe.12606.

    Study Objectives: Influence of L. reuteri Prodentis lozenges on plaque control and gingival inflammation in pregnant women.

    Study Design: R, DB, PC, During 3rd trimester and the first days after delivery

    Subjects and daily dose: 24 patients L. reuteri (4x108 CFU), 21 patients Placebo

    Results: Compared to placebo, L. reuteri Prodentis significantly reduced the Plaque index and the Gingival index. There was no effect on the inflammation marker TNF-α (in serum).

  • Clinical effect of Lactobacillus reuteri in the treatment of gingivitis: a randomized controlled clinical trial

    Bravo J. et al., Clin. Periodoncia Implantol. Rehabil. Oral vol.11 no.1 Santiago abr. 2018. doi. 10.4067/S0719-01072018000100032.

    Study Objectives: To evaluate the efficacy of L. reuteri Prodentis lozenges in the treatment of gingivitis in young adults (~19y).

    Study Design: R, DB, PC, 3 months

    Subjects and daily dose: 15 patients L. reuteri (2x108 CFU), 15 patients Placebo

    Results: Only the L. reuteri group had a significant reduction in number of sites with severe inflammation. However, both the groups had significant improvements in gingival index, plaque index and bleeding on probing.

  • Oral probiotics in the management of gingivitis in diabetic patients: a double blinded randomized controlled study

    Sabatini S. et al., J Biol Regul Homeost Agents. 2017 Apr-Jun;31(2 Suppl 1):197-202.

    Study Objectives: Pilot trial to evaluate the effect of L. reuteri Prodentis lozenges on gingivitis in diabetic patients (adults).

    Study Design: R, SB, open, 30 days

    Subjects and daily dose: 40 patients L. reuteri (4x108 CFU), 40 patients Placebo

    Results: Compared to control, L. reuteri significantly reduced the Plaque index and the Bleeding on probing.

  • Short-term effect of chewing gums containing probiotic Lactobacillus reuteri on the levels of inflammatory mediators in gingival crevicular fluid

    Twetman S. et al., Acta Odontol Scand . 2009;67(1):19-24. doi: 10.1080/00016350802516170.

    Study Objectives: To investigate the effect of L. reuteri Prodentis chewing gums on gingival inflammation and the levels of selected pro- and anti-inflammatory cytokines in gingival crevicular fluid, in adults.

    Study Design: R, DB, PC, 2 weeks + 2 weeks follow-up

    Subjects and daily dose: 13 patients L. reuteri (2 gums - 4x108 CFU), 13 patients L. reuteri (1 gum - 2x108 CFU + 1 gum placebo), 12 patients Placebo

    Results: L. reuteri significantly:
    • Decreased bleeding on probing and reduced the volume of gingival crevicular fluid
    • Dose-dependently decreased proinflammatory oral cytokines

Parodontitis

9 klinische Studien. Es folgen einige Artikel.

  • A dual-strain Lactobacilli reuteri probiotic improves the treatment of residual pockets: A randomized controlled clinical trial

    Laleman I. et al., J Clin Periodontol . 2020 Jan;47(1):43-53. doi: 10.1111/jcpe.13198.

    Study Objectives: To evaluate the effect of L. reuteri Prodentis lozenges as an adjunct to mechanical debridement on residual pockets in patients with periodontitis. 

    Study Design: R, DB, PC, 12 weeks with follow-up at 24 weeks

    Subjects and daily dose: 20 patients L. reuteri (4x108 CFU), 19 patients Placebo

    Results: At 24 weeks, the overall probing pocket depth in the L. reuteri Prodentis group was significantly lower compared to the placebo group (p=0.034). This difference was even more pronounced in moderate (4-6mm) and deep (≥7mm) pockets.

  • Effects of adjunctive probiotic L. reuteri lozenges on S/RSD outcomes at molar sites with deep pockets

    Pelekos G. et al., J Clin Periodontol. 2020 Sep;47(9):1098-1107. doi: 10.1111/jcpe.13329.

    Study Objectives: Sub-analysis of data from a previous study evaluating the effect of L. reuteri Prodentis as an adjunct to Scaling and Root Surface Debridement (S/RSD). This study evaluated changes at molars with deep pockets (PPD≥5mm). 

    Study Design: R, DB, PC, 28 days

    Subjects and daily dose: 21 patients L. reuteri (4x108 CFU), 20 patients Placebo

    Results: Compared to placebo, L. reuteri significantly improved CAL and conferred a higher probability of shallow residual pocket depth.

  • Clinical efficacy of Lactobacillus reuteri-containing lozenges in the supportive therapy of generalized periodontitis stage III and IV, grade C: 1-year results of a double-blind randomized placebo-controlled pilot study

    Grusovin M. G. et al., Clin Oral Investig. 2020 Jun;24(6):2015-2024. doi: 10.1007/s00784-019-03065-x.

    Study Objectives: Pilot study to evaluate the effect of L. reuteri Prodentis as an adjunct to Full Mouth Guided Biofilm Therapy (FM-GBT) in patients with severe and advanced forms of periodontitis (stage III and IV, grade C).

    Study Design: R, DB, PC, 3 months + 3 months washout + 3 months + 3 months washout (1 year total)

    Subjects and daily dose: 10 patients L. reuteri (4x108 CFU), 10 patients Placebo

    Results: L. reuteri Prodentis significantly reduced mean probing pocket depth at all time-points (3, 6, 9, and 12 months), sites with BOP at 6 and 9 months, and increased probing attachment level at 6 months, compared to placebo. No complications or adverse events were reported.

Periimplantäre Mukositis & Periimplantitis

9 klinische Studien. Es folgen einige Artikel.

  • Efficacy of Antibiotic Versus Probiotics As Adjuncts to Mechanical Debridement for the Treatment of Peri-Implant Mucositis

    Alqahtani F. et al., J Oral Implantol. 2022 Apr 1;48(2):99-104. doi: 10.1563/aaid-joi-D-20-00259.

    Study Objectives: To compare the efficay of L. reuteri Prodentis with antibiotics as an adjunct to mechanical debridement in the treatment of periimplant mucositis. Primary outcomes were plaque index, bleeding on probing, probing depth and crestalbone-loss, recorded at baseline and at 3-and 6-months follow-up.

    Study Design: R, Open, Lr: 21 days, Antibiotics: 7 days

    Subjects and daily dose: 14 patients MD + L. reuteri, 14 patients MD + antibiotics, 14 patients MD

    Results: At 3 months, peri-implant plaque index, bleeding on probing and probing depth were significantly lower in the probiotic group compared to the placebo group. However, at 6 months no differences were seen between the groups.

  • Efficacy of mechanical debridement with adjunctive probiotic therapy in the treatment of peri-implant mucositis in cigarette-smokers and never-smokers

    Alqahtani F. et al., Clin Implant Dent Relat Res. 2019 Aug;21(4):734-740. doi: 10.1111/cid.12795.

    Study Objectives: To evaluate the effect of L. reuteri Prodentis as adjuvant to mechanical debridement (MD) in the treatment of peri-implant mucositis in smoking and non-smoking patients.

    Study Design: R, Open, 3 weeks + follow-up at 3- and 6 months

    Subjects and daily dose: 80 in total. 40 smokers and 40 non-smokers L. reuteri (2 tabl/d): 40 (20 in each group) (4x108 CFU)

    Results: In non-smokers, the mean pocket depth, plaque index and bleeding on probing were significantly lower in the subjects that received L. reuteri Prodentis as adjunct to MD, compared to those who received MD alone at the 3 months' follow-up. At the 6 months' follow-up, there were no sign differences between the groups. In smokers, there were no significant differences at any of the time points..

  • Evaluation of the effect of probiotics in the treatment of peri-implant mucositis: a triple-blind randomized clinical trial

    Peña M. et al., Clin Oral Investig. 2019 Apr;23(4):1673-1683. doi: 10.1007/s00784-018-2578-8.

    Study Objectives: To evaluate the additional effect of L. reuteri Prodentis after mechanical debridement and 0.12% chlorhexidine in the treatment of peri-implant mucositis, compared to mechanical debridement and chlorhexidine alone.

    Study Design: R, DP, PC, 1 month + 3 months follow-up

    Subjects and daily dose: 25 patients L. reuteri (2x108 CFU), 25 patients placebo

    Results: The administration of L. reuteri did not provide any additional effect on clinical or microbiological parameters after treatment with mechanical debridement and 0.12% chlorhexidine.

Andere Studien zur Mundgesundheit

11 weitere klinische Studien. Es folgen einige Artikel.

  • Salivary IgA response to probiotic bacteria and mutans streptococci after the use of chewing gum containing Lactobacillus reuteri

    Ericson D. et al., Pathog Dis. 2013 Aug;68(3):82-7. doi: 10.1111/2049-632X.12048.

    Study Objectives: To investigate whether ingestion of L. reuteri Prodentis could influence salivary IgA levels, specific anti-mutans streptococci IgA levels and specific antibodies towards the ingested probiotic bacterium.

    Study Design: R, DB, PC 12 weeks + follow-up 1 month thereafter

    Subjects and daily dose: 11 patients L. reuteri (2x108 CFU), 12 patients Placebo

    Results: The total level of salivary IgA increased significantly within the test group. Specific IgA towards the ingested L. reuteri ATCC PTA 5289, as well as against S. mutans and S. sobrinus, decreased in the test group and the levels tended to return to pre-treatment values after the 4-week washout period. No changes were seen in the control group during the trial.

  • Lactobacillus reuteri supplements do not affect salivary IgA or cytokine levels in healthy subjects: A randomized, double-blind, placebo-controlled, cross-over trial

    Jørgensen M. R. et al., Acta Odontol Scand. 2016 Jul;74(5):399-404. doi: 10.3109/00016357.2016.

    Study Objectives: To evaluate the effect of daily ingestion of L. reuteri Prodentis on the levels of secretory IgA (sIgA) and the cytokines interleukin (IL)-1β, IL-6, IL-8 and IL-10 in whole saliva of healthy young adults, aged 18-32y.

    Study Design: R, DB, PC, crossover 3 weeks of intervention with 3 weeks of washout between, follow-up 3 weeks postintervention

    Subjects and daily dose: 41 patients L. reuteri (4x108 CFU), 41 patients Placebo

    Results: No significant differences in the concentrations of salivary sIgA or cytokines were recorded between the L. reuteri and placebo interventions or between baseline and 3 weeks postintervention levels. No side- or adverse effects were reported.

  • Presence of Lactobacillus reuteri in saliva coincide with higher salivary IgA in young adults after intake of probiotic lozenges

    Braathen G. et al., Benef Microbes. 2017 Feb 7;8(1):17-22. doi: 10.3920/BM2016.0081.

    Study Objectives: Sliva from the subjects of the Jørgensen 2016 trial, who ingested L. reuteri Prodentis, was further analysed for the presence of L. reuteri, the concentration of total protein, salivary IgA and selected cytokines. Results were compared between individuals who harbored L. reuteri after the probio-tic intervention (PCR-positive) and those who displayed sub-detection levels (PCR-negative).

    Study Design: R, DB, PC, crossover 3 weeks of intervention with 3 weeks of washout between, follow-up 3 weeks postintervention

    Subjects and daily dose: 41 patients L. reuteri (4x108 CFU), 41 patients Placebo

    Results: At baseline, 27% of the individuals displayed presence of L. reuteri and 42% were positive immediately after the three week probiotic intervention. Those with L. reuteri in saliva had significantly higher concentrations of salivary IgA and higher %IgA/protein ratio at the termination of the probiotic intake compared with subjects with non-presence of L. reuteri. No differences in the cytokine levels were observed.

  • Effect of chewing gums containing the probiotic bacterium Lactobacillus reuteri on oral malodour

    Keller M. K. et al., Acta Odontol Scand. 2012 May;70(3):246-50. doi: 10.3109/00016357.2011.640281.

    Study Objectives: To evaluate the effect of L. reuteri Prodentis chewing gums on oral malodour.

    Study Design: R, DB, PC, crossover, 14 days per product

    Subjects and daily dose: 25 patients L. reuteri (4x108 CFU), 25 patients Placebo

    Results: The probiotic chewing gums significantly decreased oral malodour assessed by organoleptic scores after the probiotic period compared to the placebo gum period. There was no effect on volatile sulphur compounds.

  • Randomized pilot study on probiotic effects on recurrent candidiasis in oral lichen planus patients

    Keller M. K. et al., Pathog Dis. 2013 Aug;68(3):82-7. doi: 10.1111/2049-632X.12048.

    Study Objectives:  A pilot study to investigate the effect of L. reuteri Prodentis lozenges on recurrent candidiasis in oral lichen planus patients.

    Study Design: R, DB, PC 16 weeks + 36 weeks follow-up

    Subjects and daily dose: 10 patients L. reuteri (6x108 CFU), 13 patients Placebo

    Results: No difference between the groups during the intervention or follow-up in terms of recurrent oral candidiasis. The study experienced recruitment problems and was therefore underpowered.

  • Effect of Probiotic Bacteria on Oral Candida in Frail Elderly

    Kraft-Bodi E. et al., J Dent Res . 2015 Sep;94(9 Suppl):181S-6S. doi: 10.1177/0022034515595950.

    Study Objectives: To investigate the effect of a daily intake of the probiotic L. reuteri Prodentis on the prevalence and counts of oral Candida in frail elderly patients living in nursing homes, and aged 60-102 years and mean age 88y.

    Study Design: R, DB, PC Multi-center 12 weeks Study product was taken at the same time as medicines, morning and early evening

    Subjects and daily dose: 84 patients L. reuteri (4x108 CFU), 90 patients Placebo

    Results: Compared to placebo, the L. reuteri group had a statistically significant reduction in the prevalence of high Candida counts (primary outcome), and the difference was statistically significant in both saliva and plaque (P < 0.05). No significant differences between the groups were noted concerning clinical signs of gingivitis, i.e. the levels of supragingival plaque or bleeding on probing. No adverse events related to the study products were reported.

* Abkürzung von Limosilactobacillus reuteri ATCC PTA 5289 & Limosilactobacillus reuteri DSM 17938. DSM = Deutsche Sammlung von Mikroorganismen und Zellkulturen; ATCC PTA = Amerikanische Sammlung von Mikroorganisamen.

Adresse

AllergyCare AG
Vordergasse 43
CH-8200 Schaffhausen

  • Diese E-Mail-Adresse ist vor Spambots geschützt! Zur Anzeige muss JavaScript eingeschaltet sein!
AGB